Experience
Sandoz, Inc.
AbbVie Biotechnology, Ltd
Successfully represented AbbVie in inter partes review (IPR) challenges related to Humira®.
Sandoz, Inc. v. AbbVie Biotechnology, Ltd, IPR2018-00002, -00156, IPR2017 -01824, -02106, -02105, PTAB, Judges Ankenbrand, Hulse, Mitchell
Finnegan client AbbVie secures non-institution decisions for Humira® patents
AbbVie Biotechnology, Ltd
AbbVie Inc.
AbbVie secures four non-institution decisions for Humira® patent
AbbVie Biotechnology, Ltd.
AbbVie Biotechnology; Abbott GmbH Ltd. v. InterLab Limited; Merck-Serono Limited
AbbVie Biotechnology; Abbott GmbH Ltd.
Abbott Biotechnology Ltd. v. Centocor Ortho Biotech Inc.
Abbott Biotechnology Ltd.
Coalition for Affordable Drugs IV LLC v. Pharmacyclics, Inc.
AbbVie Inc.; Janssen Biotech, Inc.; Pharmacyclics LLC; Pharmacyclics, Inc.
AbbVie Inc.
Sandoz Inc. v. Boehringer Ingelheim International GmbH et al.
Boehringer Ingelheim International GmbH et al.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.